Oak Thistle LLC Invests $1.72 Million in Labcorp Holdings Inc. $LH

Oak Thistle LLC acquired a new position in shares of Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,848 shares of the medical research company’s stock, valued at approximately $1,718,000.

Other hedge funds have also modified their holdings of the company. HBK Sorce Advisory LLC lifted its stake in Labcorp by 4.3% during the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock worth $254,000 after acquiring an additional 38 shares in the last quarter. Pure Financial Advisors LLC lifted its stake in Labcorp by 3.9% during the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock worth $292,000 after acquiring an additional 38 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after acquiring an additional 40 shares in the last quarter. Burney Co. lifted its stake in Labcorp by 0.5% during the 3rd quarter. Burney Co. now owns 8,819 shares of the medical research company’s stock worth $2,532,000 after acquiring an additional 42 shares in the last quarter. Finally, Advisor OS LLC increased its holdings in Labcorp by 5.4% during the 3rd quarter. Advisor OS LLC now owns 821 shares of the medical research company’s stock worth $236,000 after purchasing an additional 42 shares during the period. 95.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LH. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Piper Sandler upped their price target on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Robert W. Baird upped their price target on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. upped their price target on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Labcorp from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp currently has a consensus rating of “Moderate Buy” and an average target price of $307.70.

Labcorp Trading Up 2.2%

LH opened at $275.10 on Thursday. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $293.72. The company has a market cap of $22.67 billion, a P/E ratio of 26.30, a PEG ratio of 1.87 and a beta of 1.02. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The business’s 50-day simple moving average is $274.52 and its 200-day simple moving average is $268.89.

Labcorp (NYSE:LH) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. During the same quarter in the prior year, the business posted $3.45 EPS. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities research analysts expect that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were issued a $0.72 dividend. The ex-dividend date was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. Labcorp’s dividend payout ratio is presently 27.53%.

Insiders Place Their Bets

In other news, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jonathan C. Meltzer sold 87 shares of the stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the transaction, the executive vice president owned 2,782 shares in the company, valued at approximately $807,948.44. The trade was a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 16,113 shares of company stock worth $4,547,450. Insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.